While diquafosol tetrasodium failed to hit the primary endpoint in a Phase III trial for dry eye disease, Inspire Pharmaceuticals Inc. plans to file a new drug application amendment by the end of the second quarter. (BioWorld Today)
Axonyx Inc. lost almost two-thirds of its value on Monday with news that its lead Alzheimer's disease product, Phenserine, failed in a European Phase III trial. (BioWorld Today)